Please assess the completion status of the following clinical trial:

Trial Title: Pipamperone/Citalopram (PipCit)Versus Citalopram in the Treatment of Major Depressive Disorder(MDD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients~* 18-65 years inclusive~* Suffering from a moderate to severe MDD as defined by DSM IV with an existence of depressed mood and loss of interest/anhedonia for at least four weeks and no longer than six months for the current episode~* Diagnosis will be confirmed by the Mini International Neuropsychiatric Interview (MINI) version 5.0.0.~* Clinical global impression - severity scale (CGI-S) rating of at least four and a minimum Hamilton Depression Scale (HAM-D) 17 items total score of 18 at screen and baseline~* A non-psychotic state~* Where appropriate, male patients should agree to use barrier contraceptive measures (condoms) during the course of the study and for three months after the last dose of medication~Exclusion Criteria:~* Premenopausal females not using adequate contraceptive measures~* Considered by the investigator to be a significant risk of suicide or scoring 5 or more on the MADRS question 10~* Significant other psychiatric illness which would interfere with trial assessments - co-morbid generalised anxiety disorder (GAD) and panic disorder will be permitted where MDD is considered the primary diagnosis~* Significant physical illness which would interfere with trial assessments~* Reduced hepatic function~* Epilepsy~* History of cardiac dysrhythmia~* Alcohol intake above accepted UK ranges~* Recent (1 week) antidepressant (except for fluoxetine - 4 weeks and St John's Wort or MAOI's - 14 days), benzodiazepine or any other psychotropic medication ingestion including lithium or other mood stabilisers~* Resistant depression defined as having failed to respond to~  * Two previous antidepressants at an adequate dose ingested for at least 4 weeks during the current episode~ * To an augmentation therapy with an atypical antipsychotic drug~* Electroconvulsive therapy (ECT) for the current episode~* Formal psychotherapy or alternative treatments for one week prior to or during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Citalopram, 40 mg daily in combination with Pipamperone, 5 mg twice daily (bd)
- 2 (Type: PLACEBO_COMPARATOR): Citalopram, 40 mg daily in combination with Placebo, dummy twice daily (bd)

Based on this trial design, predict the completion outcome and termination type (if applicable).